• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2017.12094

Olanzapine in treatment of a schizophrenic patient with orthotopic liver transplant

[Notes from practice]
Leonid Bardenshteyn; Iskander Enikeev; Irina Shcherbakova; Boris Tsygankov; Igor Boev; Galina Aleshkina;

Presents a clinical case of a patient with paranoid schizophrenia and orthotopic transplant of the liver (02.12.2011). Constantly takes immunosupressivny therapy: tacrolimus, mycophenolate mofetil. Start of mental illness is, in all probability, to 2011, when first appeared the verbal deceptions of perception and ideas of its specific mission and significance. In July 2014 the patient’s mental state significantly deteriorated: he developed hallucinatory-paranoid state, katotonia-oneiric inclusions, and he was hospitalized in a psychiatric hospital. The main difficulty encountered in the management of this patient, was the choice of antipsychotic drug. As the pathogenetic treatment of schizophrenia, we used atypical antipsychotic olanzapine. The choice of this drug was due to the high clinical efficacy of olanzapine in the treatment of disease and a low risk of unwanted side effects – hepatotoxicity, extrapyramidal symptoms. It makes olanzapine the most preferred for the treatment of schizophrenia in a patient with hepatitis C and liver transplant.

Download

References:
1. Jastrebov D. V., Avedisova A. S. Some aspects of the therapy of atypical antipsychotic drugs for example olanzapine. Sovremennaja terapija v psihiatrii i narkologii. – Current therapy in psychiatry and neurology. 2012;2:10-14.
2. Gervasini G., Caballero M. J., Carrillo J. A., Benitez J. Comparative cytochrome p450 in vitro inhibition by atypical antipsychotic drugs. ISRN Pharmacol. 2013. doi: 10.1155/2013/792456
3. Ring B. J., Binkley S. N., Vandenbranden M., Wrighton S. A. In vitro interaction of the antipsychotic agent olanzapine with human cytochromes P450 CYP2C9, CYP2C19, CYP2D6 and CYP3A. Br. J. Clin. Pharmacol. 1996;41(3):181-186. doi: 10.1111/j.1365-2125.1996. tb00180.x
4. Sheehan, J. J., Sliwa J. K., Amatniek J. C., Grinspan A., Canuso C. M. Atypical antipsychotic metabolism and excretion. Curr. Drug. Metab. 2010;11(6):516-525. doi: 10.2174/138920010791636202
5. Urichuk L., Prior T. I., Dursun S., Baker G. Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions. Curr. Drug. Metab. 2008;9(5):410-418. doi:10.2174/138920008784746373

Keywords: paranoid schizophrenia, chronic hepatitis C, liver transplantation, comorbidity, antipsychotic drugs, olanzapine